SS-31 Barth syndrome FDA approval: inside the September 2025 Forzinity accelerated approval.

In September 2025, the FDA gave SS-31 (Forzinity) accelerated approval for Barth syndrome — the first real drug for a disease that has had none for thirty years.

This isn't front-page news outside the mitochondrial-disease community, but it matters. Barth syndrome is so rare most pediatric cardiologists will never see a case. Before Forzinity, the treatment was supportive care only: monitoring the heart problem (dilated cardiomyopathy), feeding kids who can't grow, and managing the chronic infections that come with their broken white blood cells.

What the FDA did is approve the first drug that targets the actual biology of Barth syndrome. Not a cure, but the first pharmacological tool aimed at the underlying defect. This article covers what the trial showed, what the FDA accepted, what comes next, and what the approval does and does not mean for the broader mitochondrial pipeline.

What is Barth syndrome, and why does elamipretide fit?

Barth syndrome is caused by mutations in the TAZ gene. TAZ codes for tafazzin, an enzyme that builds and remodels cardiolipin. Cardiolipin is a specialty lipid that lives in the inner membrane of mitochondria. Cardiolipin has four fatty-acid tails instead of the usual two. It is the structural backbone of the mitochondrial cristae, the folded inner walls where ATP is produced.

In Barth syndrome, tafazzin is non-functional. Cardiolipin is synthesized incorrectly. The cristae flatten. The protein machinery that produces ATP (the electron transport chain) destabilizes. Energy production is impaired. Oxidative damage increases. The tissues with the highest energy demands, heart muscle and skeletal muscle, are most affected. The clinical picture observed in affected individuals: cardiomyopathy, skeletal muscle weakness, chronic neutropenia, and growth failure, typically presenting in infancy.

Elamipretide doesn't fix the TAZ mutation. The broken cardiolipin is still produced. But the drug binds directly to whatever cardiolipin is there and stabilizes the cristae. The shape holds. The ATP machinery can assemble. Energy production recovers, at least partially. That's why we get a clinical response without a genetic fix.

TAZPOWER: the trial that won approval

The approval rests on the TAZPOWER program. The first phase was a 28-week randomized, double-blind, placebo-controlled trial of elamipretide administered subcutaneously once daily in Barth syndrome patients. The enrollment was small — proportionate to a disease this rare.

The 28-week trial alone wasn't enough to win approval. What it did establish: the muscle-strength and walking endpoints actually responded to the drug, and the safety profile held up in a young-adult and pediatric population. That justified moving to the long-term extension that ultimately persuaded the FDA.

The TAZPOWER open-label extension ran for 168 weeks — about three and a half years of daily injections. Of 10 patients who entered, 8 reached the endpoint. The 2024 published results in Genetics in Medicine showed sustained improvements on:

• 6-minute walk test (6MWT) — standardized distance-covered walking endpoint used across cardiac, pulmonary, and neuromuscular disease trials.
• BTHS-SA Total Fatigue score — a Barth syndrome-specific patient-reported outcome instrument measuring chronic fatigue in study participants.
• Muscle strength — the endpoint that anchored the approved label.
• Echocardiogram metrics — markers of cardiac function that decline in untreated Barth syndrome study participants.
• Cardiolipin biomarkers — direct mechanistic evidence of target engagement consistent with the proposed cardiolipin-stabilization mechanism.

The cardiolipin biomarker matters most for proving mechanism. Barth patients have a characteristic abnormal ratio of mature to immature cardiolipin in their tissues. After 168 weeks of elamipretide, that ratio normalized. The drug was visibly doing what the cell-biology model predicted in actual patients — not just an indirect functional improvement, but a direct read on the underlying defect.

SS-31

Tetrapeptide 4 aa Cardiolipin-binding

The same mitochondria-targeting tetrapeptide cited across the TAZPOWER 168-week open-label extension data. Lab-verified identity and purity for in-vitro cardiolipin and electron-transport-chain assays.

View SS-31

Why did the FDA accept muscle-strength as the endpoint?

The approved label specifies muscle-strength improvement. That came from the 6MWT and BTHS-SA improvements in TAZPOWER. The endpoint choice is significant because it reflects what the FDA accepted as adequate proof in an ultra-rare disease context.

The 6MWT has been used for decades across cardiac, lung, and muscle disease trials. It captures the combined effect of heart output, lung function, muscle endurance, and stamina in one repeatable test. For Barth syndrome — where heart, muscle, and chronic fatigue all reduce exercise tolerance — the 6MWT is a more sensitive read on overall disease burden than any single-organ test.

Accelerated approval lets the FDA approve a drug on a surrogate endpoint that's "reasonably likely to predict clinical benefit," in exchange for follow-up trials that prove actual benefit. The TAZPOWER 6MWT and BTHS-SA results cleared that bar: they're mechanistically coherent with cardiolipin stabilization, they held up over 168 weeks, and they reflect changes that meaningfully affect daily life.

The accelerated pathway is the same one many cancer drugs use. The FDA chose it deliberately for serious diseases where patients can't wait for a traditional Phase III to finish.

What does accelerated approval require next?

Approval isn't the end. The FDA requires confirmatory trials to convert this into traditional approval — or pull the drug if the confirmatory work fails. For Forzinity, that means:

• Extended TAZPOWER follow-up beyond 168 weeks to characterize long-term durability and safety.
• Hard clinical endpoints like cardiac mortality and hospitalization rates over multi-year follow-up — the data that would convert a surrogate-endpoint approval to a benefit-proven approval.
• Pediatric expansion. The current label requires patients to weigh at least 30 kg. Whether the drug is safe and effective in smaller children is the big unanswered subgroup question.
• Patient registry data. Barth is too rare for big randomized trials, so the Barth Syndrome Foundation registry will be a critical real-world evidence source.

The approval is real FDA approval — same marketing authorization, label, and prescribing requirements as any approved drug. The data-gathering just continues.

What will Forzinity cost?

Ultra-rare disease drugs typically run $300,000 to $750,000 per patient per year. Forzinity is expected to land somewhere in that range. This is substantially higher than the grey-market "SS-31" research-chemical pricing circulating in longevity research communities.

Access in the U.S. will go through specialty pharmacy distribution with insurance pre-authorization. The Barth Syndrome Foundation has built post-approval support infrastructure including reimbursement help and Medicaid coordination for pediatric patients. The orphan-drug regulations include specific access provisions for ultra-rare conditions, and Forzinity is a textbook case for using them.

The price differential between FDA-approved Forzinity and grey-market research-chemical "SS-31" reflects the distinct regulatory contexts. Grey-market vendors are not selling FDA-approved Forzinity. They are not subject to GMP manufacturing requirements. They do not provide prescribing information, post-marketing safety surveillance, or clinical support infrastructure. The approved drug and a research-grade reference compound are different products operating under different regulatory frameworks.

What does this mean for the broader pipeline?

The approval is for Barth syndrome specifically — one ultra-rare disorder with a direct mechanistic match. It's not approval for general mitochondrial disease, sarcopenia, athletic performance, or anti-aging. Those broader indications are either in active Phase III development (NuPOWER for primary mitochondrial myopathy, ReCLAIM for dry AMD, PROGRESS-HF for heart failure) or grey-market marketing claims with no trial support.

What the approval does signal: cardiolipin stabilization translates to measurable clinical benefit in at least one patient population where the cardiolipin biology is the disease. That's meaningful for the rest of Stealth's pipeline. If the mechanism works where broken cardiolipin is the genetic cause, we might see it work in other disorders where cardiolipin dysfunction is part of the picture even when it's not the root cause.

That's the bet behind NuPOWER, ReCLAIM, and PROGRESS-HF. Those readouts over the next 24 to 36 months will tell us whether Forzinity is a category-creating drug or stays a single-indication orphan therapy.

SS-31

100 mg ≥99% pure Lyophilized

D-Arg-Dmt-Lys-Phe-NH₂ · mitochondria-targeting tetrapeptide. The same reference compound used in TAZPOWER mechanistic biomarker work and ongoing Phase III development. COA available with each lot.

Learn more

Approved indication scope and trial entry criteria

The September 2025 approval established several key parameters that define the approved population and the evidentiary basis for the indication:

• Confirmed TAZ pathogenic variant required. The approved indication specifies Barth syndrome diagnosed by confirmed TAZ mutation. Genetic confirmation was an entry requirement in the TAZPOWER trial.
• Weight threshold of 30 kg. The approved label specifies study participants weighing at least 30 kg. Smaller pediatric subjects were not included in the TAZPOWER population, leaving that subgroup as an open regulatory and clinical question.
• TAZPOWER entry criteria. The trial enrolled participants with specific baseline cardiac and muscle function profiles. Published entry criteria are detailed in the TAZPOWER primary publication and OLE report.
• Orphan-drug access infrastructure. Specialty pharmacy distribution with insurance pre-authorization requirements have been established. The Barth Syndrome Foundation has developed post-approval reimbursement support infrastructure.
• Long-term administration modality. The TAZPOWER OLE documented once-daily subcutaneous administration over a 168-week period. Adherence and persistence data were reported across the study population.
• Active enrollment opportunities. NuPOWER (primary mitochondrial myopathy), ReCLAIM (dry AMD), and additional Stealth BioTherapeutics programs are in active Phase III development for related indications.

The bottom line

The FDA's September 2025 approval of Forzinity for Barth syndrome is the first disease-specific treatment for an ultra-rare mitochondrial disorder. Real, clinically meaningful, for a small but desperate patient population. The TAZPOWER 168-week data in 8 patients reaching the endpoint is the evidentiary core, supported by the cardiolipin biomarker data.

The accelerated-approval framework requires confirmatory work that will keep refining the picture for years. The approval is specifically for Barth syndrome, not for general mitochondrial disease or longevity. Grey-market "SS-31" marketing as a general longevity peptide runs ahead of the trial evidence.

For the Barth syndrome clinical community, the treatment landscape shifted from supportive care only to mechanism-directed therapy. Not a cure, but the first pharmacological tool with a disease-specific mechanism. For peptide therapeutics broadly, Forzinity is the clearest example yet of what successful translation from research-grade reference compound to commercial drug looks like.